NCT04444986 is a Phase 1 clinical trial of FAVIR 200 MG FT in Bioequivalence, sponsored by Kocak Farma.

Who is sponsoring NCT04444986?

NCT04444986 is sponsored by Kocak Farma.

What drugs are being tested in NCT04444986?

Interventions in NCT04444986: FAVIR 200 MG FT, AVIGAN 200 mg FT.

What condition does NCT04444986 study?

NCT04444986 studies Bioequivalence.

Is NCT04444986 still recruiting?

NCT04444986 is currently completed. Last updated 30 November 2020.

Last reviewed 2020-11-30 · How we verify

NCT04444986

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions

Completed Phase 1 Last updated 30 November 2020

What this trial tests

Phase 1 trial testing FAVIR 200 MG FT in Bioequivalence in 30 participants. Completed in 13 June 2020.

Timeline

5 June 2020

Primary endpoint
11 June 2020

13 June 2020

Quick facts

Lead sponsor	Kocak Farma
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	30
Start date	5 June 2020
Primary completion	11 June 2020
Estimated completion	13 June 2020
Sites	2 locations across Turkey (Türkiye)

Drugs / interventions tested

FAVIR 200 MG FT — full drug profile →
AVIGAN 200 mg FT — full drug profile →

Conditions studied

Bioequivalence — all drugs for Bioequivalence →

Sponsor

Kocak Farma — full company profile →

Who can join

Adults 18 to 40, male only, with Bioequivalence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O, Lai WF. · · 2021 · cited 39× · PMID 33031623 · DOI 10.1002/cbic.202000595
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.
Chakraborty R, Parvez S. · · 2020 · cited 35× · PMID 32739342 · DOI 10.1016/j.bcp.2020.114184

Verify or expand the search:

Other recruiting trials for Bioequivalence

Currently open trials in the same condition.

NCT07096869 — Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Pa · Phase 1 · recruiting

Other Kocak Farma trials

Trials by the same sponsor.

NCT04838080 — Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04444986 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kocak Farma
Last refreshed: 30 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04444986.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing